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ABBREVIATIONS 
 
% IBW – percentage of ideal body weight 
ASL – airway surface layer 
BAL – bronchoalveolar lavage 
BMI – body mass index 
CF – cystic fibrosis 
CFLD – cystic fibrosis-associated liver disease 
CFRD – cystic fibrosis-related diabetes  
CFTR – cystic fibrosis transmembrane regulator 
CRP – C-reactive protein 
FEV1 – forced expiratory volume in 1 second  
FFM – fat free mass 
GERD – gastroesophageal reflux disease 
IBD – inflammatory bowel disease  
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IL-1β – interleukin-1β 
IL-6 - interleukin-6 
MI – meconium ileus 
PERT - pancreatic enzyme replacement therapy 
PI – pancreatic insufficient 
REE – resting energy expenditure 
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TNF-α - tumor necrosis factor-α 
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ABSTRACT 
 
The Complexity of Malnutrition in Cystic Fibrosis. Romana Prskalo 
 
Cystic Fibrosis (CF) is the most common life-limiting genetic disease of Caucasian 
populations. It is a disease inherited in an autosomal recessive fashion, and the defect lies in 
the gene encoding the cystic fibrosis transmembrane regulator (CFTR) - a chloride channel 
regulating ion transport across the apical surface of secretory epithelial cells. The main 
clinical manifestations are pancreatic insufficiency and progressive obstructive pulmonary 
and gastrointestinal disease. Malnutrition in patients with CF is a common clinical feature in 
patients of all ages, and a common cause of failure to thrive and growth failure in both 
infancy and childhood. Although it is not as common of a problem as it was in the past, it still 
contributes to increased morbidity and premature death in patients with CF.  
 
Malnutrition in CF is a result of the complex interaction of various interrelated and unrelated 
factors, which lead to increased energy requirements, increased energy losses, and a 
decreased caloric intake- resulting in a negative energy balance. The organ dysfunction 
caused by the systemic manifestations of the disease also contribute to malnutrition. Exocrine 
pancreatic insufficiency is a major cause of maldigestion and malabsorption. It can be treated 
with pancreatic enzyme replacement therapy (PERT), but even with optimal therapy, it does 
not always result in optimal nutrition and growth. This indicates that pancreatic insufficiency 
does not account for all of the nutritional issues in CF, as was once thought, pointing to other 
factors such as progressive lung disease, gastrointestinal disease, psychosocial issues, and 
comorbid conditions, among others, that may contribute and influence the development of 
malnutrition in patients with CF.  
 
The challenge with malnutrition is that there is an absence of a specific, etiological treatment 
for patients with CF and in the meantime, there exists only enzyme replacement therapy and 
supportive treatment, which may help reduce energy losses, but do not eliminate the problem. 
Specific etiological and genetic therapy is still far in the future, and for now, the solution is to 
vigilantly monitor nutritional status and growth and follow patients on a lifelong basis.  
 
Key words: cystic fibrosis, malnutrition 
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SAŽETAK  
 
Složenost pothranjenosti u cističnoj fibrozi. Romana Prskalo 
 
Cistična fibroza (CF) najčešća je nasljedna bolest u bjelačkoj populaciji koja bitno skraćuje 
životni vijek. Nasljeđuje se autosomno recesivno, a posljedica je mutacije gena CFTR (od engl. 
cystic fibrosis transmembrane regulator ili hrv. transmembranski regulator povodljivosti za 
cističnu fibrozu). CFTR funkcionira kao kloridni kanal koji regulira prijenos iona preko apikalne 
površine sekretornih epitelnih stanica. Simptomi i težina bolesti značajno variraju od bolesnika 
do bolesnika, no osnovne kliničke manifestacije CF su kronična plućna bolest i bolest probavnog 
sustava. Malapsorpcijski sindrom prisutan je u svim dobnim skupinama i glavni je uzrok slabijeg 
napredovanja u dječjoj dobi. Malapsorpcija nije toliko veliki terapijski problem kao u prošlosti, 
no još uvijek značajno pridonosi morbiditetu i preuranjenoj smrti bolesnika s CF.  
 
Pothranjenost u CF rezultat je složene interakcije različitih povezanih i nepovezanih čimbenika, 
koji zajedno dovode do povećanih energetskih potreba, povećanih gubitaka energije i smanjenog 
unosa kalorija s posljedičnom negativnom energetskom ravnotežom. Disfunkcija organa 
uzrokovana sustavnim pojavama bolesti također pridonosi neishranjenosti. Insuficijencija 
egzokrine gušterače osnovni je uzrok poremećene digestije i malapsorpcije. Može se liječiti 
nadoknadom enzima, no čak ni optimalna supstitucijska terapija ne dovodi uvijek do optimalne 
kontrole malapsorpcije. To upozorava na to da insuficijencija gušterače nije jedini uzrok 
malnutricije u CF, kao što se nekoć mislilo, ukazujući na druge dodatne potencijalne čimbenike 
koji mogu pridonijeti i utjecati na razvoj pothranjenosti u bolesnika s CF. To su između ostalog 
progresivna plućna bolest, gastrointestinalna bolest, psihosocijalne okolnosti ili simultana 
prisutnost jedne ili dvije kronične bolesti. 
 
Izazov u liječenju malnutricije u CF leži u nedostatku specifične, etiološke terapije za bolesnike 
oboljele od CF. Trenutno je osnovno liječenje supstitucijska terapija pankreasnim enzimima i 
potporne mjere koje pomažu kontroli gubitaka energije, ali često ne rješavaju problem 
uhranjenosti u potpunosti. Specifična etiološka i genetska terapija stvar je budućnosti, a za sada je 
rješenje da se pažljivo prati nutritivni status i rast pacijenta, i to doživotno. 
 
Ključne riječi: cistična fibroza, neishranjenost 
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1 INTRODUCTION TO CYSTIC FIBROSIS 
 
1.1 Epidemiology of Cystic Fibrosis 
 
Cystic fibrosis (CF) is the most common, life-limiting autosomal recessive disease occurring 
in Caucasian populations. [1] It is characterized by the production of thick, viscous secretions 
affecting all organs and tissues with mucus-secreting glands, for example, the airways, 
pancreas, gastrointestinal tract, biliary tract, reproductive tract, and sweat glands. 
The prevalence of the disease varies by ethnicity and is considered to be between 1,500-3,000 
cases per 100,000 live births in Caucasian populations [2], such as those found in Europe, 
Northern America, and Australia. Approximately 1 in 25-30 people of Caucasian descent are 
asymptomatic carriers of the disease [3] CF can affect people of all racial and ethnic groups, 
although the prevalence is low in African Americans and very low in those of Asian descent. 
[4] It must be noted, however, that there are great variations in prevalence among different 
geographical areas and subsets of populations even among Caucasians.  
 
The association between CF and malnutrition is a strong one. A cross-sectional analysis 
performed by the German CF quality assurance group has revealed that the prevalence of 
malnutrition in children aged 2-6 years old is 19%. This percentage increased significantly 
with age up to 38% in adults, [5] indicating that malnutrition is not just a feature of disease in 
childhood, but appears to be a lifelong issue, especially now that the mean life expectancy of 
CF patients has increased well beyond what it used to be several years ago. 
 
1.2 Genetics of Cystic Fibrosis 
 
CF is a rare, multisystem genetic disease that is inherited in an autosomal recessive pattern. 
The mutation involves a defective single large gene located on chromosome 7q31.2 that 
encodes the cystic fibrosis transmembrane regulator (CFTR) protein. [6] This encoded protein 
functions as a regulated chloride channel which, in turn, may regulate the activity of other ion 
channels at the apical surface of the cell. [7, 8, 9]  
 
CFTR is normally present on the apical surface of the cell membrane of exocrine glands and 
several other tissues (including the lungs, biliary tract, intestinal epithelium, epididymis, vas 
deferens, and cervix, among others). Expression of clinical disease requires defective 
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mutations in both alleles of the CFTR gene, altering the structure of the CFTR protein, and 
causing dysfunction of the chloride ion channel. This leads to failure of exchange of chloride 
and sodium ions as well as bicarbonate and water molecules in and out of the cell, and 
changes in the composition of secretions secreted by and lining epithelial surfaces in the 
lungs, pancreas, intestines, liver, exocrine sweat glands, bile ducts, and epididymis. [7] 
 
There are currently over 2,000 mutations of the gene encoding the CFTR protein listed in the 
CFTR mutation database [10], but only a minority, around 300, cause cystic fibrosis. [11] The 
single most common mutation is ΔF508 (also known as delta F508, delF508, 
c.1521_1523delCTT, or p.Phe508del,), caused by the deletion of three base pairs resulting in 
the absence of phenylalanine at position 508 of the CFTR protein. [6] This deletion results in 
CFTR protein misfolding, impaired cellular processing of the protein, and defective delivery 
of CFTR to the cell surface. [8] Literature shows that approximately 70% of Caucasian CF 
patients have one copy of the ΔF508 mutation while 50% are homozygous for this mutation. 
[6] In 2013, 86.4% of patients in the CF Registry were found to have at least one copy of the 
ΔF508 mutation, with homozygotes making up 46.5% and heterozygotes making up 39.9% of 
this number. [12] The remaining percentage of cases were caused by many of the other 
disease-causing mutations, which occur at a much lower frequency and are individually rare; 
for example, the next most common mutation, G542X, was found in only 4.6% of patients. 
[12] 
 
While the predominant mutation in Caucasians, particularly of Northern European origin, is 
ΔF508, it must be emphasized that certain mutations are found at a different frequency in 
certain ethnic groups. For example, in Ashkenazi Jews, the ΔF508 was found at a 
considerably lower frequency (31%) compared to North American and Northern European 
populations. The predominant CF mutations in Ashkenazi Jews were found to be W1282X 
(48%), ΔF508 (30%) and G542X (12%) [13], in contrast to Northern European and North 
American populations in which the ΔF508 mutation accounted for over 70% of all mutations, 
followed by G551D (2.6%), G542X (2.3%), and hundreds of other infrequent variants. [14, 15] 
Moreover, the frequency of the ΔF508 mutation varies greatly from country to country, even 
within European populations. For example, the ΔF508 mutation was found at a prevalence of 
87.5% in Denmark compared to only 31.0% in Lithuania. [16] 
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Different mutations cause different defects in the CFTR protein, resulting in a spectrum of 
disease severity ranging from mild to severe phenotypes. [17] There are five, or in some newer 
literature, six, classifications of gene mutations causing CF based on the level or the degree 
of dysfunction of CFTR activity; with (generally) more severe disease phenotype caused by 
mutations in classes I-III, and milder disease in classes IV-V/VI [18] - see table 1.  
 
Table 1. Classification of CFTR* mutations [18] 
 
Class Effect on CFTR protein Functional 
CFTR 
CFTR apical 
expression 
Examples of 
mutations 
I Defective production (absent 
synthesis) 
No No G542X, W1281X, 
1717-1G>A 
II Impaired processing No No F508del, I507del, 
N1303K 
III Defective regulation of CFTR 
chloride channel 
No Yes G551D, G1349D, 
V520F 
IV Altered conductance of CFTR 
chloride channel 
Reduced Yes R117H, R347P, 
R334W 
V Reduced synthesis of CFTR 
protein 
Reduced Reduced A445E, D565G, 
3849+10kbC>T 
VI Less stable CFTR protein Reduced Reduced c.120del123 
 
*CFTR = cystic fibrosis transmembrane regulator 
 
Aside from the mutations in the CFTR protein, various other genetic and environmental 
factors, including mutations in other genes excluding CFTR as well as various gene modifiers 
[8] of the CF phenotype, may influence the expression of clinical disease. Therefore, it must 
be noted that mutation analysis does not always provide accurate prognostic information. It is 
also known that the interaction between a certain genetic predisposition and the environment 
plays a role in the development as well as the heterogeneity in the severity of the disease, 
although the exact mechanisms for how this occurs are not yet fully understood. 
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1.3 Phenotypic variation in Cystic Fibrosis 
 
One of the main characteristics of CF is that it is a disease of variable severity and course 
between and within affected individuals. Today, newborn screening can be performed for CF 
allowing the possibility to diagnose the disease at the beginning of the child’s life, allowing 
therapeutic intervention, particularly nutritional support, to be arranged before serious 
complications of the disease arise. The currently available newborn screening method 
measures the raised serum concentration of immunoreactive trypsinogen using the Guthrie 
blood spot test. [19] An abnormal newborn screen requires further diagnostic testing to confirm 
the disease and this is performed using a chloride sweat test (the “gold standard” for 
diagnosing CF) and molecular DNA analysis. The majority of genetic tests screen for the 
most common CF mutations occurring in a specific population. According to the Consensus 
Guidelines from the Cystic Fibrosis Foundation, diagnosis of CF can be made when the 
individual has a positive newborn screen along with evidence of CFTR dysfunction, in the 
form of a positive sweat chloride test (sweat chloride level ≥60mmol/L), and the presence 
of 2 CFTR disease-causing gene mutations on genetic analysis. It is not enough to make a 
diagnosis based on clinical suspicion alone. Other tests of CFTR function may also be 
performed in specialized centres if indicated. [20] 
 
Currently, approximately 60% of CF patients are diagnosed through newborn screening, [20-22] 
while around 20% of those not diagnosed by NBS develop their first presentation of disease 
shortly after birth, in the form of meconium ileus (MI), a type of intestinal obstruction caused 
by inspissated meconium. [23] Other affected patients commonly present early in life, usually 
within the first year, with the classical symptoms of CF such as failure to thrive, steatorrhea, 
cholestatic jaundice, and chronic respiratory infections, among others. [6] These symptoms 
may also be found in patients who have been screened for CF. Other CF patients with milder 
disease phenotypes may exhibit subclinical forms or atypical features of the disease and may 
be diagnosed at a later age or even proceed undiagnosed. Patients with milder CFTR 
genotypes (see table 1) generally have milder lung disease and pancreatic insufficiency to a 
lesser degree, with delayed expression and slower progression of disease. [24] 
 
The most common CFTR mutation, ΔF508, which is found in the majority of patients with 
the severe form of disease, has a strong correlation with PI, particularly in a patient who has 
inherited two severe alleles. An individual that is homozygous for the ΔF508 mutation 
 
 
10
usually has PI, [25] which is relevant because most of these patients will need aggressive and 
lifelong nutritional support to prevent growth failure and malnutrition. 85% of all CF patients 
have PI leading to maldigestion, which is defined by evidence of steatorrhea following 72-
hour fecal fat testing. [26] The pancreatic sufficient (PS) phenotype, on the other hand, is 
associated with the presence of one or two “mild” CFTR mutations (see table 1) including 
R117H, R334W, R347P, A455E, and P574H. [27]  
 
Thus, as a result of the vast number of different CFTR gene mutations and resulting spectrum 
of disease phenotypes, all categories of disease severity may be present within the population. 
There exists a broad variability of clinical expression between patients, both in terms of the 
various modes of disease presentation as well as the onset of progression of the disease, and it 
is this wide spectrum of disease variability that makes the disease unpredictable, in terms of 
diagnosis and possibly treatment.  
 
 
1.4 Pathogenesis of Cystic Fibrosis 
 
The pathophysiological cascade of CF begins with a genetic mutation encoding the CFTR 
protein, which leads to altered ion channel flux, leading to abnormally viscous and 
dehydrated epithelial secretions in many tissues as well as impaired mucociliary clearance in 
the respiratory system. [18] While the exact pathogenesis of CF leading to organ dysfunction is 
not completely understood, it can be said that the defective composition of secretions 
significantly contributes to the clinical manifestations of the disease. In the lungs, the 
respiratory epithelium becomes impermeable to chloride ions and reabsorbs excessive 
sodium leading to a relative dehydration of airway secretions, leading to obstruction, chronic 
inflammation and eventual fibrosis. A similar manifestation occurs in other organ systems, 
including the pancreas, gastrointestinal tract, hepatobiliary tract, and genitourinary tract, 
among others. The pathophysiological mechanisms of some of these systems will be 
discussed separately and in more detail later on, with regard to how they contribute to the 
disease and their association with malnutrition. 
 
In the sweat glands of patients with CF, there is no presence of obstruction or pathologic 
abnormalities like in the other organ systems, but rather an abnormality of sodium chloride 
homeostasis. The sweat ducts are unable to reabsorb chloride ions due to the absence or 
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dysfunction of CFTR, and therefore, sodium is also poorly reabsorbed. The resulting sweat 
contains concentrated secretions high in sodium and chloride ions, contributing to excessive 
sweating and the “salty” sweat described by parents of children with CF. [8] This pathology of 
the sweat glands as a result of CFTR dysfunction is the basis of the chloride sweat test used 
in the diagnosis of CF. 
 
Ultimately, the phenotype of CF determines the disease severity and progression, and as there 
is such a wide spectrum of severity in CF, disease presentation can be diverse. However, the 
“classical” form of CF - the fully expressed disease - is characterized by the following 
predominant features; progressive lung disease, pancreatic dysfunction leading to intestinal 
malabsorption, elevated sweat electrolytes, and infertility in males or subfertility in 
females.[23] These features begin early on in life and contribute to the state of malnutrition 
observed in a majority of CF patients. The “classical” form is what this review will primarily 
be dealing with, as malnutrition plays a significant role in the “classical”, severe form of CF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12
2 THE ENERGY IMBALANCE 
 
The precise etiology of malnutrition in CF is unclear, and it can be said, therefore, that it is 
the result of a complex interaction of both related and unrelated factors that alter the energy 
balance. This includes reduced energy intake, increased energy expenditure, impaired 
digestion and absorption, and excessive energy losses. The total energy balance in any 
individual is based on the input versus the output, and in the case of CF, patients often have a 
predominantly negative energy balance. Specifically, malnutrition in CF is a consequence of 
an imbalance between high energy requirements, reduced intake, and excessive energy 
losses. The energy imbalance is further aggravated by the cycle of inflammation, obstruction, 
and infection in the respiratory and gastrointestinal systems. 
 
 
 
Figure 1. The interconnected factors leading to an energy deficit and weight loss as lung 
function deteriorates [28] 
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2.1 Increased energy requirements 
 
The increased energy requirements are primarily due to acute pulmonary exacerbations, 
superimposed on the presence of chronic pulmonary infection and inflammation, all leading 
to increased work of breathing and the presence of a hypermetabolic state. Currently, it is 
recommended for a patient with CF to have an energy intake between 110-200% of the 
recommended daily intake (RDA) compared to the general population. CF patients also 
require a greater fat intake, between 35-40% of calories, compared to the general population. 
[29] These greater energy requirements are mostly due to the presence of an increased resting 
metabolic rate (RMR) in CF patients, leading to an increased resting energy expenditure 
(REE). [30-32] 
 
The energy balance is further aggregated by acute pulmonary exacerbations which 
additionally increase RMR and energy requirements from an estimated 50-100% of normal. 
[33] Furthermore, the RMR remains elevated for some weeks even after the inflammation is 
resolved before returning back to the baseline level. Additionally, progression of obstructive 
lung disease, even in clinically stable CF patients, has been shown to lead to increases in 
RMR as lung function, in the form of forced expiratory volume in 1 second (FEV1), declines. 
[34]  
 
It has also been suggested that dysfunction of the CFTR gene itself may have a direct effect 
on basal metabolism and lead to higher energy requirements at the cellular level. [35] The 
mechanism behind this appears to be a defect in the mitochondrial energy transporter, which 
as a result of the CFTR mutation, leads to a two-to three-fold increase in oxygen 
consumption in the affected tissues of patients with CF, compared to unaffected tissues. [36] It 
can be said, therefore, that increased energy requirements are a consequence of both 
dysfunction at the cellular level, as well as at the somatic level of the organism, due to the 
pathologic consequences of the disease. [34] 
 
2.2 Increased energy losses  
 
The increased energy losses occur in the form of intestinal malabsorption, caused mainly by 
pancreatic exocrine insufficiency, which leads to fecal energy losses in the form of both 
steatorrhea and diarrhea. As a result of pancreatic endocrine dysfunction, there are energy 
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losses through the urine in the form of glucosuria, a manifestation of cystic fibrosis-related 
diabetes (CFRD). Other losses in the stool include carbohydrates, proteins, bile salts and 
mucus, but to a lesser extent than fats. Even with optimal pancreatic enzyme replacement 
therapy (PERT) in CF patients, these losses are not normalized, and it has been shown that 
children with CF have stool energy losses ranging from 5-20% of oral energy intake even 
when using pancreatic enzyme replacement, compared to 1-6% losses in healthy controls. [37] 
Furthermore, the influence of certain drugs, particularly antibiotics, on the colonic flora, may 
cause alterations that lead to changes in digestion – including decreased fermentation of 
carbohydrates, deconjugation of bile acids, and diarrhea. The role of comorbid conditions 
such as celiac disease, inflammatory bowel disease (IBD), irritable bowel syndrome, and 
cystic fibrosis-related liver disease (CFLD) may also influence energy losses, further 
aggravating digestion and malabsorption. 
 
2.3 Decreased energy intake 
 
The decreased energy intake occurs in the form of reduced appetite which is influenced by a 
variety of factors and can be divided into chronic suboptimal intake and acute suboptimal 
intake. Chronic suboptimal intake is a result of several factors, most importantly, perhaps, 
due to the psychological aspect of the disease, causing anorexia, anxiety, and depression. The 
influence of cytokines and presence of a chronic inflammatory state also contribute to the 
reduced intake and lead to mechanisms contributing to the development of cachexia. Several 
somatic symptoms including gastroesophageal reflux disease (GERD), abdominal pain, colic, 
gas, nausea, vomiting, and chronic cough may all contribute to the reduced intake of food and 
decreased appetite. Acute pulmonary exacerbations may cause anorexia both during and 
following the episodes and result in an acute suboptimal intake. Furthermore, medications 
used in CF may contribute to reduced appetite and caloric intake. 
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3 SYSTEM-SPECIFIC MANIFESTATIONS OF CYSTIC FIBROSIS 
CONTRIBUTING TO MALNUTRITION 
 
3.1 Lung disease 
 
The presence of severe pulmonary disease is one of the main features of CF contributing to 
malnutrition. Several studies, including a longitudinal analysis performed by the German CF 
quality assurance (CFQA) group [5], have exhibited the co-dependant relationship between 
malnutrition and lung function in CF. It was shown that a decrease in weight was associated 
with a corresponding decrease in lung function (in the form of FEV1, as measured by 
spirometry) whereas patients who were of normal weight and who had improved nutrition 
remained at the same or even improved their FEV1 values. Furthermore, the presence of 
malnutrition has been recognized as an independent negative prognostic factor and main 
predictor of impaired survival in CF. [38] In the study, low % ideal body weight (IBW) and 
low % of predicted FEV1 were shown to be independent and highly accurate prognostic 
indicators for the probability of death within 5 years in patients with CF. Additionally, 
progressive pulmonary disease is recognized as the main negative prognostic factor in 
patients with CF. [2] Malnutrition in patients in CF is important because it is related to lung 
function; in so that there is a strong positive correlation between degree of malnutrition and 
severity of lung disease; the presence of malnutrition parallels the decreases in lung function. 
Hence, severity of lung disease is an indicator of prognosis and survival, with decreasing 
lung function leading to decreased survival and an increase in morbidity and mortality. [5, 38] 
More importantly, it has been shown that nutritional status has a significant effect on 
pulmonary disease progression and survival in CF patients, and that malnutrition developing 
from an early age could influence lung development and function later in life. Indexes of 
growth and nutrition, including height for age (HFA), weight for age (WFA), %IBW, and 
body mass index (BMI) in early childhood can be used as strong predictors of pulmonary 
function in later childhood, with weight loss being associated with worse pulmonary function 
and symptoms and signs of lung disease. [39] This data demonstrates the importance of 
malnutrition in regards to lung function and how the two factors are interrelated.  
 
Pulmonary disease in CF patients generally follows a course of chronic and recurrent 
infections, inflammation, and obstruction within the airways. The pathophysiological 
mechanism behind the pulmonary disease seen in patients with severe phenotypes of CF is 
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the result of a CFTR mutation leading to defective or absent CFTR expressed in respiratory 
epithelial cells of the bronchi and bronchioles. [40, 41] Dysfunction or absence of CFTR leads 
to altered ion flux as well as impaired fluid secretion leading to the production of abnormal 
respiratory secretions lining the epithelial cells, collectively referred to as the airway surface 
layer (ASL). Normal, healthy airway epithelia have the ability to absorb or secrete ions and 
fluid through various ion channels including epithelial sodium channel (ENaC), CFTR, and 
calcium activated chloride channels (CaCCs). [42] In patients with CF, altered ion transport 
leads to decreased chloride and bicarbonate ion secretion as well as enhanced absorption of 
sodium ions. The reduced bicarbonate concentration leads to acidification of the ASL, which 
may negatively influence microbial killing and host defences. [18] Fluid exchange is also 
impaired as a result of the altered ion transport, leading to excessive dehydration of secretions 
composing the ASL. Furthermore, there is also excessive mucin production [41], resulting in 
thick and viscous secretions that coat the airways and cannot be adequately removed by 
mucociliary clearance as they are in normal, healthy lungs. [8] The accumulation of mucus 
leads to narrowing and obstruction of the airways and as a result, increased work of 
breathing. The hyperviscous secretions lead to mucus plugging within the airways, which 
creates an anaerobic environment and predisposes the airway epithelium to chronic microbial 
colonization with various microorganisms including Staphyloccocus aureus, Pseudomonas 
aeruginosa, Burkholderia cepacia, Haemophilus influenza, and Aspergillus fumigatus, 
among others. [6] 
 
Consequently, as microbial colonization ensues, activated neutrophils are recruited and begin 
to infiltrate the airways, releasing various cytokines and factors, including interleukin-6 (IL-
6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and leukotriene β4 that contribute 
and further aggravate the pro-inflammatory milieu. Reduced levels of anti-inflammatory 
cytokines and proteases have also been found in the airways of CF patients. [8] Thus, the cycle 
of pulmonary obstruction, infection and inflammation ensues.  
 
The presence of a chronic inflammatory state accompanied by chronic infection in the 
pulmonary system play a particularly large role in the contribution to malnutrition because 
the subsequent decreased lung function and increased work of breathing result in an increase 
in energy expenditure both at rest, in the form of an increased RMR, as well as during 
activity. As a result, both REE and total energy expenditure are increased. Energy 
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expenditure increases further in the presence of an acute exacerbation, which further 
increases the RMR and energy requirements for patients with CF.  Exacerbations are 
frequently accompanied by acute weight loss, which can be attributed to a decreased appetite 
along with a reduced caloric intake [28], in addition to increased energy losses, in the form of 
increased RMR. Moreover, acute pulmonary exacerbations are frequently accompanied by a 
decline in pulmonary function which can be, in part, attributed to the amplification of the 
inflammatory cascade due to the additional production of various pro-inflammatory factors, 
cytokines [43], and C-reactive protein (CRP) [44]. Patients in the terminal stages of pulmonary 
disease often have chronic anorexia [28], which contributes to malnutrition and weight loss. 
Therefore, lung inflammation and infection, both chronic as well as acute exacerbations, 
increase the work of breathing and contribute to the increased total energy expenditure seen 
in CF patients.  
 
The production of highly viscous mucus that causes airway obstruction, impaired mucociliary 
clearance, as well as chronic microbial colonization are the main drivers of the chronic 
pulmonary disease in CF. These features further contribute to the recurrent pulmonary 
infections and eventual destruction of lung parenchyma, as well as to the chronic, persistent 
inflammatory state within the pulmonary system. [18] Progressive obstruction, infection, and 
inflammation eventually leads to tissue destruction and fibrosis. 
It is well recognized that severe lung disease is the main cause of morbidity and mortality in 
CF. End-stage lung disease in CF patients ultimately leads to respiratory failure, which is 
responsible for approximately 80% of patient mortality. [22] 
 
 
3.2 Pancreatic dysfunction  
 
Pancreatic dysfunction is one of the main features contributing to malnutrition in CF. The 
pathogenesis behind pancreatic exocrine dysfunction in CF includes impaired pancreatic fluid 
secretion as well as altered composition of the secretions. In the pancreas, CFTR is expressed 
primarily at the apical surface of the ductal epithelial cells. [45] Under normal circumstances, 
pancreatic fluid contains various digestive enzymes released by the pancreatic acinar cells, 
suspended in an alkaline solution high in bicarbonate and chloride, released by the ductal 
cells. The pancreatic fluid, when stimulated, is released into the small intestine and 
contributes to the digestion of fats, proteins, and carbohydrates within the duodenal contents. 
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The alkaline pH of the pancreatic fluid is essential, as an alkaline medium is needed in the 
duodenum and rest of the small intestine for optimal functioning of the digestive enzymes, as 
well as for the neutralization of gastric acid. [18] 
 
In patients with the pancreatic insufficient (PI) phenotype of CF (around 90% of all CF 
patients) [26, 46], however, the composition of pancreatic secretions differs. Absent or impaired 
function of CFTR in pancreatic ductal cells leads to altered ion transport across the ductal 
epithelium and leads to decreased chloride [47] as well as bicarbonate secretion [48] within the 
ductal lumen. The altered ion flux also influences the fluid secretion across the ductal 
epithelium, leading to impaired movement of fluid into the lumen resulting in dehydrated 
secretions. Normally, acinar cells release proteins (primarily pancreatic enzymes) which 
become suspended within the dilute, alkaline (and bicarbonate-rich) fluid in the pancreatic 
lumen. In CF, the impaired anion transport leads to production of fluids that are more acidic 
and of smaller volume than normal. This causes hyperconcentration and precipitation of the 
proteins within the ducts, leading to obstruction and destruction of the duct lamina, and 
ultimately results in pancreatic insufficiency. [47] 
 
The change in composition of the pancreatic secretions influences the digestive process 
within the small intestine and contributes to maldigestion and malabsorption. As a result of 
the decreased concentration of bicarbonate in the pancreatic secretions, the pH within 
duodenum is decreased, and the acid from the incoming gastric contents is not neutralized by 
the normally alkaline, bicarbonate-rich pancreatic fluids. The hyperacidic pH within the 
duodenum impairs digestion by causing denaturation of the digestive enzymes, particularly 
lipase. Decreased lipase activity is the driving force behind steatorrhea and subsequent fat 
malabsorption [47], which is responsible for the great fecal energy losses seen in CF patients 
with PI. 
 
Another element of pancreatic dysfunction in CF is the deficiency of pancreatic enzymes. As 
a result of the production of dehydrated pancreatic fluid, mucin concentration increases and 
contributes to obstruction within the ducts. The thick secretions block the passage of 
pancreatic enzymes moving through the ducts and prevents the delivery of pancreatic 
enzymes to the duodenum. This results in an inability of the gut to adequately digest food and 
absorb nutrients from it, resulting in malabsorption. The obstruction of the ducts with 
pancreatic enzymes also results in “auto digestion” of the pancreatic ducts and acini, leading 
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to progressive dysfunction and damage of ductal and acinar cells. [18] This leads to 
progressive acinar destruction and decreased enzyme production over time. [49] Exocrine 
pancreatic insufficiency occurs in the majority of CF patients early on in the course of 
disease, due to destruction of pancreatic acini as well as ductular obstruction. These 
inflammatory and destructive processes in the pancreas usually begin in utero, and progress 
after birth during which time the infant is usually asymptomatic. Currently, approximately 
90% of CF patients progress to pancreatic insufficiency and require PERT early on in 
childhood. [46] 
 
 In addition to the progressive destruction of the pancreatic ducts and acini, there may be 
subsequent damage to β cells. [18] Destruction of the endocrine portion of the pancreas 
ultimately leads to impaired glucose tolerance and CF-related diabetes mellitus (CFRD), 
which is present in around 25% of children and 40% of adult patients, making it the most 
common comorbidity in patients with CF. [33] The relevance of CFRD in regards to 
malnutrition is the loss of energy through the urine (glucosuria). Associated metabolic 
features and complications of diabetes mellitus may further contribute   
 
 
3.3 Gastrointestinal disease  
 
There is a myriad of elements within the gastrointestinal system that contribute to 
malnutrition in patients with CF. Several components have already been mentioned. The best 
known are a direct consequence of pancreatic insufficiency, which leads to maldigestion and 
malabsorption in the intestines leading to energy losses (primarily fats) through the stool. 
Another key component is the presence of hyperacidity in the duodenum. The reason for the 
lower duodenal pH is primarily due to decreased bicarbonate in pancreatic secretions. 
However, it is also in part due to decreased bicarbonate secretion by the duodenal epithelium 
itself [47] where there is abnormal CFTR expression in CF patients. The decreased duodenal 
pH leads to denaturation of pancreatic enzymes (if present) [50], which contributes to 
steatorrhea and fat malabsorption.  
Furthermore, the absorption of fats in the intestine is also dependant on the presence of bile 
salts, and in the case of CF, bile salts are denatured and precipitated as a result of the 
decreased duodenal pH. [51] Moreover, there is an increased loss of bile salts in the stool and 
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impairment of enterohepatic recirculation due to impaired ileal reabsorption, possibly due to 
the thick, mucus secretions lining the epithelium or to small intestinal bowel overgrowth 
(SIBO). [18] Impaired reabsorption of bile acids leads to excessive levels within the intestines, 
and their loss through the stool, which may even lead to secretory diarrhea in some 
patients.[52] Bile salts are normally required to emulsify and solubilize lipids in the intestinal 
lumen, so their dysfunction and excretion further impairs lipid digestion and absorption and 
contributes to fat malabsorption and fecal energy losses. 
 
CFTR within the gastrointestinal tract is relatively weakly expressed in the gastric mucosa 
and highly expressed in both the small and large intestinal epithelium. [53] CFTR dysfunction 
in the intestine, as in other secretory organs (excluding the sweat glands), leads to reduced 
volume of secretions within the lumen and overproduction of mucins, that contribute to 
obstruction within the gut. 
 
 The accumulation of thick, viscid mucus is one of the main pathological features of CF, and 
contributes to many sequelae of the disease. Furthermore, thick sluggish bile from the 
hepatobiliary system, once it enters the intestines, may contribute to the development of 
various intestinal obstructive syndromes as well as chronic constipation. In extreme cases, 
acute obstruction within the intestinal lumen may manifest as MI at birth, and distal intestinal 
obstruction syndrome (DIOS) seen in older children or young adults. [54] In the long-term, the 
thick, viscid secretions throughout the intestinal tract may contribute to constipation and 
obstipation [51]. Although these pathologies do not contribute to malnutrition per say, they are 
vital in the manifestation of disease.  
 
Furthermore, the thick, viscous mucus that accumulates in the intestinal lumen further limits 
absorption of nutrients from the intestinal epithelium, contributing to malabsorption. Excess 
mucus may also lead to bacterial overgrowth in the small intestine. SIBO is frequent in CF, 
and may contribute to malabsorption and maldigestion, and subsequent symptoms such as 
bloating, flatulence, abdominal pain, diarrhea and steatorrhea. [55] These bacteria in the small 
intestine may compete with the host for ingested nutrients, and may also deconjugate bile 
salts, decreasing their ability to emulsify lipids. [56] Alterations in the colonic bacterial flora 
may also occur as a result of the chronic, as well as short-term, use of antibiotics as well as 
other medications. [51] 
 
 
21
 Altered motility also contributes to malabsorption in CF, and includes both rapid gastric 
emptying as well as decreased small intestinal transit time. [49] This leads to inadequate 
mixing of food with pancreatic secretions and bile, and decreased time for nutrients to be 
absorbed within the small intestine, both of which contribute to maldigestion and 
malabsorption.  
 
Regarding the presence of chronic inflammation within the gastrointestinal tract, several 
studies have demonstrated the increased expression of inflammatory markers and cytokines 
within the intestinal lumen of CF patients. [57] The presence of chronic inflammation within 
the intestines contributes to the hypermetabolic state found in patients with CF, and leads to 
increased energy expenditure. Other causes contributing to inflammation include the presence 
of IBD (including Crohn’s disease and ulcerative colitis) and celiac disease. [18] These 
conditions act as comorbidities in patients with CF and further aggravate the presence of 
malnutrition by contributing to maldigestion, malabsorption, and a chronic inflammatory 
state. One should also consider the possibility of acute bacterial, viral, and parasitic infections 
in some patients as contributing factors (although short-term) to malabsorption and 
malnutrition.  
 
Furthermore, the presence of fibrosing colonopathy, a complication of prolonged treatment 
with excessive doses of PERT, may contribute to malnutrition. Fibrosing colonopathy is of 
variable presentation, and may include features such as abdominal pain and distention, 
altered bowel habits, and failure to thrive. It may also lead to formation of strictures causing 
recurrent bowel obstruction, and if clinically significant, require colonic resection. [58] 
 
In conclusion, a variety of entities within the gastrointestinal tract may contribute to the 
presence of malnutrition in patients with CF. The majority cause maldigestion and 
malabsorption and lead to increased energy losses through the stool. Furthermore, abdominal 
complaints such as pain, bloating, constipation, and GERD may contribute to a reduced 
appetite and result in a decreased caloric intake, additionally worsening the energy 
imbalance. The presence of comorbid conditions affecting the gastrointestinal tract as well as 
infections may further contribute to malabsorption and increased energy losses. 
 
 
 
 
22
3.4 Hepatobiliary disease 
 
CFLD is present in around 30% of patients with CF, and encompasses a variety of 
manifestations ranging from neonatal cholestasis to persistent elevations of transaminases, 
hepatomegaly, steatosis, biliary obstruction, and focal biliary cirrhosis – the characteristic 
hepatic lesion. [59] Eventually, there may be progression to fibrosis and finally, portal 
hypertension and cirrhosis. The development of CFLD is associated with presence of a more 
severe phenotype of the disease (mutation classes I-III), although it also appears to be 
associated with other gene polymorphisms. [33, 60] 
 
CFLD is considered an important cause of morbidity as well as mortality in patients with CF, 
as it accounts for 2.9% of the overall mortality in patients with CF, making it the third most 
common [61] (after cardiorespiratory and transplant-related causes) and significant non-
pulmonary cause of death. [12] Liver disease in CF has even been hypothesized as an 
independent risk factor for mortality [62], in addition to lung disease and malnutrition. 
 
The expression of CFTR in the liver is restricted to the apical surface of the biliary 
epithelium [63]; there is no CFTR expression on the hepatocyte. As a result, abnormal 
secretions are produced by the epithelium lining the biliary ducts and cause ductal 
obstruction, similar to that observed in the pancreas. Due to impaired anion transport across 
the apical membrane, combined with the overproduction of mucus by the biliary epithelial 
cells, there is production of viscous and inspissated bile by the ductal epithelium. This 
inspissated bile causes obstruction within the intrahepatic biliary ducts, and with time leads to 
chronic damage, inflammation and fibrosis of the liver. [18]  
 
The clinical manifestations of malnutrition are further aggravated by deterioration of liver 
disease because the abnormal bile is unable to emulsify lipids in the intestines. Furthermore, 
the bile salts become deconjugated and precipitate in the intestines as a result of lowered 
duodenal pH, further aggravating fat malabsorption and steatorrhea. Cholestasis, together 
with pancreatic insuffiency, contributes to fat malabsorption [64] which predisposes to 
deficiencies of fat-soluble vitamins in the liver. Steatosis, or fatty liver, has also been 
associated with malnutrition in some patients, as well as with deficiencies of essential fatty 
acids choline and carnitine. [65] 
 
 
 
23
The development of portal hypertension may also contribute to malnutrition in a 
multifactorial way, leading to limited nutrient absorption, increased resting energy 
expenditure, anorexia, and reduced caloric intake. [65] Patients with cirrhosis may also 
progress to liver synthetic failure characterized by hypoalbuminemia, vitamin K dependent 
coagulopathy, and high bilirubin. [62] 
 
In conclusion, presence of CFLD has been shown to negatively affect nutritional status in CF 
in a multifactorial way. It includes increases in resting energy expenditure, fat malabsorption 
(due to the combination of cholestasis and pancreatic insufficiency), reduced nutrient intake, 
and abnormal metabolism of nutrients. [64] It has also been shown that severe liver disease 
appears to significantly increase the risk of developing CFRD, [66] which may contribute to 
the complexity of malnutrition in CF. 
 
 
3.5 Cytokine activity 
 
Chronic infection and inflammation within the respiratory and gastrointestinal tracts are 
associated with the presence of a chronic inflammatory and hypermetabolic state in CF 
patients. In the lungs, chronic airway colonization and infection with persisting 
microorganisms are thought to trigger the cells of the immune system and promote migration 
of activated neutrophils to the airways. The mechanisms leading to inflammation in the CF 
lung include the interactions between various immune and cellular components, as well as 
release of numerous pro-inflammatory mediators and cytokines which cause tissue 
inflammation and destruction. These processes progressively lead to declining lung function 
and ultimately premature death in a majority of CF patients. [67] 
 
The presence of a chronic inflammatory state in patients with CF is demonstrated by 
increased levels of inflammatory markers and pro-inflammatory cytokines, including TNF-α, 
CRP, interleukin 1β (IL-1β) and IL-6, as well as certain “stress-response” hormones such as 
catecholamines and cortisol. [43] In the lung, it was found that patients with CF had 
significantly increased levels of pro-inflammatory cytokines, including IL-1β, 6, 8, and TNF-
α,  in samples of bronchoalveolar lavage (BAL) fluid compared to healthy controls. It was 
also shown that CF patients had decreased concentrations of natural cytokine antagonists 
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such as IL-1 receptor antagonist (IL-1Ra) and soluble TNF receptors (TNF-sR) compared to 
healthy controls. [68] 
 
Macrophages seem to play a crucial role in the inflammatory processes within the chronically 
infected lung, as demonstrated by Bonfield et al. [68] It was shown that the majority of pro-
inflammatory cytokines are produced by alveolar macrophages in the lungs of patients with 
CF in response to chronic infection with various microorganisms (in particular S. aureus and 
P. aeruginosa). Other cell types, including activated neutrophils as well as T-lymphocytes 
may also contribute to the production of pro-inflammatory mediators. A study by Tiringer et 
al. [69] demonstrated significant upregulation of Th1- (interferon-γ), Th2- (interleukins-5 and 
13), Th17- (interleukin-17A), and Th17-related cytokines (IL-1β, IL-6) in the BAL fluid of 
patients with CF.  
 
Increased levels of inflammatory mediators in the lungs as well as GI tract [57, 70] contribute to 
the chronic inflammatory and catabolic state found in patients with CF. Many cytokines, 
particularly TNF-α, have the ability to stimulate lipolysis, muscle catabolism, and to increase 
REE in patients with CF. [31, 71] Pro-inflammatory cytokines may also have a negative 
influence on bone mineral density, which can further contribute to a low body weight and 
malnutrition. It was found that circulating levels of inflammatory mediators, such as IL-6 and 
TNF-α, were higher in patients with a low fat free mass (FFM) compared to patients with a 
normal FFM, indicating that patients with low body weight were more prone to a catabolic 
state than patients of a healthy body weight. Patients with a reduced FFM were also shown to 
have decreased bone mineral density, in the presence of an inflammatory and catabolic state. 
[43] 
 
Therefore, release of pro-inflammatory cytokines and factors promotes the presence of a 
chronic inflammatory state that leads to progressive worsening of lung function and tissue 
destruction. Moreover, worsening lung function further exacerbates malnutrition, leading to a 
vicious cycle of increased energy requirements and increased energy losses. Furthermore, 
inflammatory mediators and cytokines may directly activate pathways leading to the 
development of a catabolic state, and may cause a similar presentation to that of cachexia 
found in many patients with other chronic or malignant diseases. As a result, patients with CF 
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have increased energy requirements and resting energy expenditure compared to healthy 
peers. [31]  
 
 
3.6 Medications 
 
Certain medications used in the treatment of CF may have an influence on the metabolic state 
of the patient as well other physiological consequences. They may decrease appetite, cause 
changes in taste, or have abdominal side effects, [72] and so lead to a decreased caloric intake. 
Inhaled β2-adrenergic agonists (ex. salbutamol, salmeterol) are medications commonly used 
in CF patients in treatment of lung disease, in conjunction with physiotherapy, especially 
during pulmonary exacerbations. They have a sympathomimetic effect, and are used to 
produce bronchodilation by directly acting on the β2-adrenoreceptors on the bronchial smooth 
muscle. They also inhibit the release of inflammatory mediators from mast cells and 
monocytes, and increase mucus clearance by acting on the cilia. [73] Long-term use of 
salbutamol (a β2-agonist) in patients with CF has been shown to increase REE, although the 
mechanism of action behind this is not fully understood. Also, REE increased by 10% within 
the first hour after administration of salbutamol [74], indicating that the long-term effect of β2-
agonist therapy may be significant in relation to malnutrition if it is used several times a day, 
as it may lead to a chronically increased REE, increasing total daily energy expenditure and 
energy requirements. 
 
Corticosteroids, both inhaled and systemic, are also frequently used during periods of acute 
pulmonary exacerbations. Corticosteroid use in clinical doses has been shown to negatively 
influence skeletal muscle strength by inducing myopathy, leading to limb muscle weakness 
and reduced muscle mass in patients with CF. [75] Treatment with inhaled corticosteroids 
(ICS) in children with CF has proven to not be beneficial, with no positive effect on lung 
function, and may also negatively affect growth. [76] The study by De Boeck et al. showed 
that children using high doses of inhaled fluticasone (an ICS) grew less than children in the 
placebo group, and had growth impairment which persisted for 12-24 months after the 
medication was discontinued.  
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3.7 Psychosocial issues  
 
As CF is a chronic and multifactorial disease, most patients require various lifelong therapies 
and treatments in order to delay disease progression and improve quality of life. A strong 
emphasis is placed on maintaining adequate nutrition, chest physiotherapy, PERT, and 
medications to control disease, which be difficult for patients and their families to deal with. 
The burden of performing all the therapies, and the particularly strong focus on food intake, 
may make the process of eating and mealtimes stressful, and may cause stress, anxiety, and 
depression [72], particularly in the adolescent population. A strong focus is also placed on 
weight gain, often from the diagnosis of the disease, which may lead to body image issues 
and disordered eating behaviors. [77] Currently, the target BMI is 22 for female patients with 
CF and 23 for males. [78] It is not readily acceptable for adolescents and young adults with CF 
to purposefully maintain a low weight and insist on dieting because these patients at the time 
of pulmonary exacerbations have lower or no nutritional reserve and deteriorate much more 
rapidly and become undernourished much faster in comparison to their well-nourished 
counterparts. This may strongly compromise their disease progression and alter their 
prognosis in the long-term. 
 
It has been shown that patients with CF have higher rates of anxiety and depression compared 
to the general population [79], with anxiety being more prevalent than depression across the 
lifespan. One international epidemiological study has shown the prevalence of anxiety and 
depression to be two-to-three times higher in patients with CF and their caregivers than in the 
community [80]. Symptoms of anxiety and depression have both been shown to lead to poorer 
disease outcomes, increased morbidity, and decreased quality of life. Although no direct 
associations have been found, it can be postulated that mental health symptoms may affect 
health outcomes, such as nutrition and lung disease, and worsen disease severity by leading 
to poor adherence and management of disease. [79] 
 
Although eating disorders are not more prevalent in adolescents with CF compared to their 
healthy counterparts, eating disturbances are, with around 53% of CF adolescents showing 
disturbed eating attitudes compared to 40-47% in the general population. Out of this number, 
18.8% of females and 7.1% of males reported participating in weight-loss behaviours, 
although the average BMI of the sample group was already at the lower limit of the “healthy” 
weight range. [81] This indicates that the higher levels of behavioural and psychological 
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problems present in the CF population may be even more detrimental to the development of 
malnutrition. 
 
Another aspect of CF that may contribute to psychological distress is CF-related pain. A 
study looking at the prevalence of pain in CF patients found that 59% of children and 89% of 
adults had at least one episode of pain during the last month [82]. This pain may be related to 
the disease itself, and involve the abdomen, back, head or chest, or to procedures. Pain may 
be a potential complication of CF and may lead to consequences such as decreased quality of 
life, limited physical activity, and psychological distress. 
 
Various psychosocial issues may lead to a decreased caloric intake in patients with CF, and it 
has been shown that patients with severe pulmonary disease are prone to depression and other 
psychological issues, which may lead to chronic anorexia. [28] Pulmonary exacerbations as 
well as acute infections lead to anorexia and a decreased caloric intake, often resulting in 
acute weight loss.  
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CONCLUSION 
 
The causes of malnutrition in CF are complex and multifactorial. As a consequence of the 
genetic mutation causing CFTR dysfunction in various organs and tissues, abnormal 
secretions are produced which lead to inflammation, obstruction, and organ dysfunction. As a 
result, patients with the severe, “classical” form of CF suffer from pancreatic insufficiency, 
chronic respiratory disease, recurrent respiratory infections, intestinal malabsorption, and 
CFLD which may lead to the development of malnutrition and low body weight. Various 
other comorbidities and factors affecting food intake may worsen malnutrition including 
CFRD, psychosocial aspects of the disease, and medications, among others. Furthermore, 
symptoms such as chronic cough, nausea and vomiting, GERD, and abdominal pain, may 
further contribute to a decreased food intake and contribute to malnutrition. In addition, 
patients with CF are often hypermetabolic and in a state of chronic inflammation. Cytokine 
activity and various immune and endocrine factors contribute to increased energy 
expenditure, often leading to weight loss. Acute infections involving the respiratory and 
gastrointestinal tracts further aggravate the hypermetabolic state and decrease energy intake 
by causing anorexia and catabolism.  
 
Malnutrition, although an expected clinical feature of CF, should never be accepted as an 
untreatable condition. Not only does malnutrition worsen the patient’s prognosis and disease 
outcome, by influencing their lung function, it also affects their quality of life. Therefore, 
after optimizing PERT and vitamin supplementation, one should always look for other 
possible contributing causes of malnutrition and attempt to detect and control them and target 
these issues therapeutically.  
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